BRCA2 and cancer: Patients with germline mutations of DNA damage repair genes (BRCA1, BRCA2, or NTHL1) had a later evolutionary onset of dissemination than patients with triple-proficient cancers (P = 0.03 by Wilcoxon’s test; Figure 4B).